# Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts

> **NCT01608243** · PHASE1 · COMPLETED · sponsor: **Stallergenes Greer** · enrollment: 94 (actual)

## Conditions studied

- Asthma
- House Dust Mite Allergy

## Interventions

- **BIOLOGICAL:** SLIT tablets of house dust mite allergen extracts
- **BIOLOGICAL:** Matching placebo

## Key facts

- **NCT ID:** NCT01608243
- **Lead sponsor:** Stallergenes Greer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2014-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01608243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01608243, "Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01608243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*